Trial reportClinical drug investigation2017
Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions.
Trial report in Clinical drug investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02089451 (A Trial Comparing the Pharmacokinetic Properties of FIAsp After Different Injection Regions and Routes of Administration in Healthy Subjects), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Trial Comparing the Pharmacokinetic Properties of FIAsp After Different Injection Regions and Routes of Administration in Healthy Subjects
Who cites it
16 citing papers in PubMed.
- Pharmacokinetic and Pharmacodynamic Characteristics of Insulin Icodec After Subcutaneous Administration in the Thigh, Abdomen or Upper Arm in Individuals with Type 2 Diabetes Mellitus.Clinical drug investigation · 2023Trial
- Fast-Acting Insulin Aspart Use with the MiniMedDiabetes technology & therapeutics · 2021Trial
- Determining Losses in Jet Injection Subcutaneous Insulin Delivery: A Model-Based Approach.Journal of diabetes science and technology · 2023Article
- Does Food Affect the Pharmacokinetics of Non-orally Delivered Drugs? A Review of Currently Available Evidence.The AAPS journal · 2022Review
- Case of type 2 diabetes mellitus with edema resulting in subcutaneous insulin resistance syndrome.Journal of diabetes investigation · 2021Article
- Impact of Accelerating Insulin on an Artificial Pancreas System Without Meal Announcement: An In Silico Examination.Journal of diabetes science and technology · 2021Article
- Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences.Clinical pharmacokinetics · 2020Review
- Factors Influencing Insulin Absorption Around Exercise in Type 1 Diabetes.Frontiers in endocrinology · 2020Review
- Preparation, characterization, and pharmacodynamics of insulin-loaded fumaryl diketopiperazine microparticle dry powder inhalation.Drug delivery · 2019Article
- Delayed insulin absorption correlates with alterations in subcutaneous depot kinetics in rats with diet-induced obesity.Obesity science & practice · 2019Article
- Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus.Clinical pharmacokinetics · 2019Review
- Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide.Pharmaceutical research · 2019Article
- Basal insulin reductions in anticipation of multiple exercise sessions in people with type 1 diabetes-a clinical perspective.Annals of translational medicine · 2018Article
- Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability.Journal of diabetes research · 2018Review
- Pharmacodynamics of Insulin Preparations Administered in Different Subcutaneous Injection Sites: Are There Differences Between Healthy Subjects Versus Diabetic Patients?Clinical drug investigation · 2017Article
- Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas.Clinical drug investigation · 2017Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFast-acting insulin aspart (faster aspart) is insulin aspart set in a new formulation with faster initial absorption after subcutaneous administration. This study investigated the pharmacokinetic properties, including the absolute bioavailability, of faster aspart when administered subcutaneously in the abdomen, upper arm or thigh.
methodsIn a randomised, open-label, crossover trial, 21 healthy male subjects received a single injection of faster aspart at five dosing visits: 0.2 U/kg subcutaneously in the abdomen, upper arm and thigh, intramuscularly in the thigh and 0.02 U/kg intravenously. Blood sampling for pharmacokinetics was performed pre-dose and frequently thereafter until 12 h post-dose (8 h after intravenous administration).
resultsOnset of appearance (~3 min), time to 50% of maximum concentration (t
conclusionThe current study supports the ultra-fast pharmacokinetic characteristics of faster aspart across different injection regions, with administration in the abdomen and upper arm resulting in greater early exposure than in the thigh. ClinicalTrials.gov identifier: NCT02089451.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.